Compare CDMOs specializing in small molecule drug product formulation, tableting, encapsulation, and coating. Filter by dosage form, batch size, and regulatory approvals.
406 companies listed
Small molecule drug product manufacturing turns your API into the tablet, capsule, or injectable a patient actually takes. The hard part isn't making one clinical batch. It's finding a partner who can carry the process from a 20,000-unit Phase I lot to a validated commercial line without a mid-program tech transfer that resets your timeline. Ask three things before you shortlist. Does the CDMO run your dosage form at both clinical and commercial scale under one roof? If your molecule is BCS Class II or IV, do they have real bioavailability-enhancement experience (spray drying, hot melt extrusion, amorphous solid dispersions), or just a brochure? And can they show a batch record and stability package that held up under an FDA pre-approval inspection? The CDMOs below list small molecule drug product as a core capability.
Small molecule drug product manufacturing transforms the API into the final dosage form patients receive. This includes granulation, blending, compression (tablets), encapsulation, film coating, and packaging. Each step requires precise process control to ensure dose uniformity, dissolution performance, and stability.
Bioavailability enhancement is a growing need. Many new chemical entities have poor aqueous solubility (BCS Class II/IV), requiring advanced formulation technologies: spray drying, hot melt extrusion, nanoparticle milling, amorphous solid dispersions, and lipid-based drug delivery systems. CDMOs with these capabilities command premium positioning.
Italy
Doppel Farmaceutici Srl is an Italian CDMO operating since 1994, specializing in contract manufacturing and packaging of finished dosage forms for pharmaceutical companies. The company offers formulation development, R&D, manufacturing of soft and hard gelatin capsules, tablets, oral liquids, and semi-solids, along with full packaging services.
United States
Enteris BioPharma (now MOD3 Pharma, acquired by Aptar Pharma) was a US-based CDMO specializing in the development and manufacture of difficult-to-formulate oral drug products. Operating from a 32,000 sq ft FDA-inspected, cGMP-compliant facility in northern New Jersey, the company offered custom formulation development and clinical trial manufacturing services.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.